Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

Abstract

A blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3) was tested for efficacy in a primate model. Aotus nancymai monkeys were vaccinated with yeast-expressed MSP3 before a lethal challenge with Plasmodium falciparum parasites. Five of 7 control monkeys had acute infections and required treatment to control parasitemia. Only 1 of 7 monkeys vaccinated with MSP3 required this treatment. The efficacy of the MSP3 vaccination appeared to be comparable to that of MSP1(42), a leading asexual vaccine candidate, in response to which 2 monkeys experienced acute infections. In the MSP3-vaccinated group, protection correlated with prechallenge titers of antibody to MSP3. In the MSP1 and control groups, protection correlated with antibody to MSP3 raised by challenge infection.

• Authors: Hajime Hisaeda, Allan Saul, Joshua J Reece, Michael C Kennedy, Carole A Long, Louis H Miller, Anthony W Stowers
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 185 Issue 5 Pg. 657-64 (Mar 01 2002) ISSN: 0022-1899 [Print] United States
• PMID: 11865423 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Protozoan
• Antigens, Bacterial
• Bacterial Proteins
• Malaria Vaccines
• Vaccines, Synthetic
• major surface protein 3, Anaplasma marginale

Topics

• Animals
• Antibodies, Protozoan (blood)
• Antigens, Bacterial
• Aotidae
• Bacterial Proteins (administration & dosage, genetics, immunology)
• Malaria Vaccines (administration & dosage, immunology)
• Malaria, Falciparum (prevention & control)
• Plasmodium falciparum (immunology)
• Saccharomyces cerevisiae (genetics, metabolism)
• Vaccination
• Vaccines, Synthetic (administration & dosage, immunology)